Core Viewpoint - Artiva Biotherapeutics is hosting a virtual event to discuss initial safety and translational data for its AlloNK® therapy in combination with monoclonal antibodies for autoimmune diseases, indicating a favorable tolerability profile and effective patient management in outpatient settings [1][6]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing safe and effective cell therapies for autoimmune diseases and cancers [3]. - The company's lead program, AlloNK®, is an allogeneic, off-the-shelf NK cell therapy designed to enhance the efficacy of monoclonal antibodies in driving B-cell depletion [3]. - Artiva was founded in 2019 as a spin-out from GC Cell, acquiring exclusive worldwide rights to NK cell manufacturing technology [3]. Clinical Trials and Data - Initial safety data from 32 patients treated with AlloNK + monoclonal antibody therapy shows a favorable tolerability profile and feasibility for outpatient management [1][6]. - The therapy demonstrates uniform and consistent deep B-cell depletion, supporting its intended mechanism of action [1][6]. - AlloNK is currently being evaluated in three ongoing clinical trials targeting B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease [3]. Upcoming Event - The virtual webcast will take place on November 12, 2025, at 8 a.m. ET, featuring a live Q&A session following the presentation [2][6]. - A replay of the webcast will be available on the company's website [2].
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®